scholarly journals Empirical use of antibiotic therapy in the prevention of early onset sepsis in neonates: a pilot study

2016 ◽  
Vol 3 ◽  
pp. 603-613 ◽  
Author(s):  
Mohamed Mansor Manan ◽  
Nazedah Ain Ibrahim ◽  
Noorizan Abd. Aziz ◽  
Hanis Hanum Zulkifly ◽  
Yaser Mohammed Ali Al-Worafi ◽  
...  
Keyword(s):  
Pilot Study ◽  
Antibiotic Therapy ◽  
Early Onset ◽  
Early Onset Sepsis

Neonatal Early-Onset Sepsis Calculator and Antibiotic Therapy—Reply

2020 ◽  
Vol 174 (5) ◽  
pp. 508
Author(s):  
Niek B. Achten ◽  
Claus Klingenberg ◽  
Frans B. Plötz
Keyword(s):  
Antibiotic Therapy ◽  
Early Onset ◽  
Early Onset Sepsis ◽  
Sepsis Calculator

Neugeborenensepsis: Prokalzitonin-orientierte Antibiotikatherapie

2017 ◽  
Vol 221 (05) ◽  
pp. 214-216
Keyword(s):  
Decision Making ◽  
Randomised Controlled Trial ◽  
Antibiotic Therapy ◽  
Antibiotic Stewardship ◽  
Early Onset ◽  
Controlled Trial ◽  
Early Onset Sepsis ◽  
Randomised Controlled

Stocker M et al. Procalcitonin-guided decision making for duration of antibiotic therapy in neonates with suspected early-onset sepsis: a multicentre, randomised controlled trial (NeoPIns). Lancet 2017; pii:S0140-6736(17)31444-7 Kommentar zur Studie: Schuetz P, Mueller B. Procalcitonin-guided antibiotic stewardship from newborns to centennials. Lancet. 2017; pii: S0140-6736(17)31628-8

scholarly journals Markers of NETosis Do Not Predict Neonatal Early Onset Sepsis: A Pilot Study

2020 ◽  
Vol 7 ◽  
Author(s):  
Carolin U. Stiel ◽  
Chinedu U. Ebenebe ◽  
Magdalena Trochimiuk ◽  
Laia Pagarols Raluy ◽  
Deirdre Vincent ◽  
...  
Keyword(s):  
Pilot Study ◽  
Early Onset ◽  
Early Onset Sepsis

Use of Procalcitonin-Guided Decision-Making to Shorten Antibiotic Therapy in Suspected Neonatal Early-Onset Sepsis: Prospective Randomized Intervention Trial

Neonatology ◽  
2010 ◽  
Vol 97 (2) ◽  
pp. 165-174 ◽  
Author(s):  
Martin Stocker ◽  
Matteo Fontana ◽  
Salhab el Helou ◽  
Karl Wegscheider ◽  
Thomas M. Berger
Keyword(s):  
Decision Making ◽  
Antibiotic Therapy ◽  
Early Onset ◽  
Intervention Trial ◽  
Early Onset Sepsis ◽  
Randomized Intervention

scholarly journals Empedobacter brevis causing early onset sepsis and pneumonia in a neonate: case report and review of literature

2018 ◽  
Vol 5 (2) ◽  
pp. 654
Author(s):  
Laxman Basani ◽  
Roja Aepala
Keyword(s):  
Case Report ◽  
Antibiotic Therapy ◽  
Nosocomial Infections ◽  
Early Onset ◽  
Term Neonate ◽  
Review Of Literature ◽  
Gram Negative ◽  
Early Onset Sepsis ◽  
The Family ◽  
Compromised Patients

Empedobacter brevis, a gram negative non-motile bacillus that belongs to the family Flavobacteriaceae rarely causes infection in adults and is exceptionally rare in neonates. E. brevis is ubiquitous in the environment, causing nosocomial infections especially in debilitated and immuno-compromised patients with only one case being reported in a neonate. We report a case of early onset sepsis and pneumonia in a term neonate caused by E. brevis that was successfully treated in our unit. Awareness regarding this uncommon pathogen and initiation of appropriate antibiotic therapy improves the outcome and prevents mortality. To the best of our knowledge, this is the second case of E. brevis sepsis reported in a neonate.

Neonatal early onset sepsis in Middle Eastern countries: a systematic review

2020 ◽  
Vol 105 (7) ◽  
pp. 639-647 ◽  
Author(s):  
Nadim Khalil ◽  
Heather B Blunt ◽  
Zhongze Li ◽  
Tyler Hartman
Keyword(s):  
Systematic Review ◽  
Middle East ◽  
Antibiotic Therapy ◽  
Neonatal Mortality ◽  
Early Onset ◽  
High Income ◽  
Empirical Antibiotic Therapy ◽  
Middle Income ◽  
Middle Income Countries ◽  
Early Onset Sepsis

BackgroundEarly onset neonatal sepsis (EOS) accounts for a significant portion of neonatal mortality, which accounts for 46% of global under five child mortality.ObjectiveThis systematic review studies the bacterial aetiology of EOS in the Middle East, susceptibility patterns to recommended empirical antibiotic therapy and whether this differs between high-income and middle-income countries in the region.MethodsArticles were collected from Medline, Web of Science, the Cochrane Library and Index Medicus for the Eastern Mediterranean Region. The articles included in our systematic review met the following criteria: published after January 2000, data relevant to the Middle East, data specific for early onset sepsis, no language restriction. Data on aetiology and susceptibility were extracted from prospective and retrospective studies. Risk of bias was assessed using the Newcastle-Ottawa Scale. This study focused on EOS but does include data regarding neonatal late-onset sepsis antibiotic susceptibility. The data regarding coagulase-negative Staphylococcus species were excluded from final analysis, as possible contaminants. The protocol for this systematic review was registered on PROSPERO: CRD42017060662.Results33 articles from 10 countries were included in the analysis. There were 2215 cases of culture-positive EOS, excluding coagulase-negative Staphylococcus. In middle-income countries, Klebsiella species (26%), Staphylococcus aureus (17%) and Escherichia coli (16%) were the most common pathogens, in contrast to group B Streptococcus (26%), E. coli (24%) and Klebsiella (9%) in high-income countries. Overall susceptibility to ampicillin/gentamicin and third-generation cephalosporin were 40% and 37%, respectively, in middle-income countries versus 93% and 91%, respectively, in high-income countries.ConclusionsEOS in middle-income countries was more likely to be due to Gram-negative pathogens and less likely to be susceptible to empirical antibiotic therapy. This has important public health implications regarding neonatal mortality in the Middle East region.

scholarly journals C-Reactive Protein, Procalcitonin, and White Blood Count to Rule Out Neonatal Early-onset Sepsis Within 36 Hours: A Secondary Analysis of the Neonatal Procalcitonin Intervention Study

2020 ◽  
Author(s):  
Martin Stocker ◽  
Wendy van Herk ◽  
Salhab el Helou ◽  
Sourabh Dutta ◽  
Frank A B A Schuerman ◽  
...  
Keyword(s):  
Antibiotic Therapy ◽  
Early Onset ◽  
Blood Count ◽  
Intervention Study ◽  
Secondary Analysis ◽  
White Blood Count ◽  
C Reactive Protein ◽  
Reactive Protein ◽  
Early Onset Sepsis ◽  
Rule Out

Abstract Background Neonatal early-onset sepsis (EOS) is one of the main causes of global neonatal mortality and morbidity, and initiation of early antibiotic treatment is key. However, antibiotics may be harmful. Methods We performed a secondary analysis of results from the Neonatal Procalcitonin Intervention Study, a prospective, multicenter, randomized, controlled intervention study. The primary outcome was the diagnostic accuracy of serial measurements of C-reactive protein (CRP), procalcitonin (PCT), and white blood count (WBC) within different time windows to rule out culture-positive EOS (proven sepsis). Results We analyzed 1678 neonates with 10 899 biomarker measurements (4654 CRP, 2047 PCT, and 4198 WBC) obtained within the first 48 hours after the start of antibiotic therapy due to suspected EOS. The areas under the curve (AUC) comparing no sepsis vs proven sepsis for maximum values of CRP, PCT, and WBC within 36 hours were 0.986, 0.921, and 0.360, respectively. The AUCs for CRP and PCT increased with extended time frames up to 36 hours, but there was no further difference between start to 36 hours vs start to 48 hours. Cutoff values at 16 mg/L for CRP and 2.8 ng/L for PCT provided a sensitivity of 100% for discriminating no sepsis vs proven sepsis. Conclusions Normal serial CRP and PCT measurements within 36 hours after the start of empiric antibiotic therapy can exclude the presence of neonatal EOS with a high probability. The negative predictive values of CRP and PCT do not increase after 36 hours.

Sign in / Sign up

Export Citation Format

Share Document